个人介绍：

  2008-2018年于沈阳药科大学-四川大学药学专业学习，获药学学士及药物化学博士学位。2018-2020年，分别于哈尔滨医科大学-深圳大学-澳门科技大学进行博士后研究工作，2020年11月加入深圳技术大学药学院。发表SCI论文50余篇，授权专利10余项，获省部级科技进步奖3次。主持包括国家自然科学基金，科技部重大专项子课题，博士后基金，广东省自然科学基金青和深圳市基础研究基金10余项。

科研项目：

1. 国家自然科学基金面上项目，澜沧民间药用植物野独活属中Miliusane类特色成分靶向EIF3D抗糖酵解依赖亚型三阴性乳腺癌的构效关系及作用机制研究（82674888），2027.01-2030.12，49万，主持。

2. 国家自然科学基金青年项目，双靶向ATAD2/PAK1抗三阴性乳腺癌的小分子抑制剂的设计合成及机制研究（82003580），2021.01-2023.12，24万，主持。

3. 科技部重大专项-重大新药创制子课题，中药民族药组分资源库建设（2018ZX09735-005），2019-2021，845.0万元，主持。

4. 博士后面上一等，ATAD2抑制剂的设计合成及抗三阴性乳腺癌的机制研究（2019M650213），2019-2020，12万元，主持。

5. 广东省基础与应用基础研究青年基金，靶向ATAD2小分子抑制剂设计合成及抗三阴性乳腺癌作用机制研究（2019A1515110482），2020.01-2022.12，10万元，主持。

6. 广东省基础与应用基础研究面上基金，双靶向PAK1/CARM1抗BRCA1突变型三阴性乳腺癌的小分子抑制剂的设计及作用机制研究（2024A1515012317），2024.01-2026.12，10万元，主持。

7. 深圳市基础研究面上项目，基于DEL技术靶向DKK1-LRP5/6的PPI小分子抑制剂的设计、合成及抗TNBC免疫逃逸机制研究（JCYJ20250604144930041），2026.01-2028.12，30万元，主持。

8. 深圳市基础研究面上项目，基于结构的靶向ATAD2小分子抑制剂设计合成及抗三阴性乳腺癌作用机制研究（JCYJ20190808171803553），2020.02-2023.02，30万元，主持。

9. 深圳市基础研究高校稳定支持计划项目，三阴性乳腺癌中双靶向BRD4/PAK1的小分子抑制剂的设计合成及机制研究（20220717181409001），2022.10-2025.09，19.6万元，主持。

代表成果：

   代表性SCI期刊论文：

1. Weiji Chen^#, Xiaoling Cheng^#, Xi Zhao^#, Zixuan Chen^#, Yupei Lai^#, Wenli Hao^#, Zhendan He^#, Wenhong Lin^#, Yan Wu^#, Yaping Guo^#, Dabo Pan*, Le Zhou*, Dahong Yao*. Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment. J Med Chem. 2026, 69(14):16834-16877.

2. Xiaoling Cheng, Weiji Chen , Wenli Hao, Yaping Guo, Jin Zhang, Chao Song, Zhendan He*, Haiqiang Wu*, Dahong Yao*. Design, synthesis, and biological evaluation of selective cytotoxicity-derived Miliusol derivatives inducing profound TNBC regression in vivo. Bioorg Med Chem. 2026, 138:118680.

3. Xiaoling Cheng, Shuangshuang Ma, Wenli Hao, Xi Zhao, Yaping Guo, Jin Zhang, Le Zhou*, Zhendan He*, Dahong Yao*. Fenticonazole targets NF-κB p105/p50 to suppress triple-negative breast cancer via ROS-mediated ER stress and apoptosis. Biochem Pharmacol. 2026, 10:117788.

4. Jin Zhang^#, Lin fia^#, Xiya Chen^#, Yan Wu, Xiaohan Sun, Ling Zou, XiaolingCheng, Jingnan Huang, Hongchao Zhou, Lingyun Dai, Le Zhou, Zhendan He, Bo Liu*, Yue Hao*, Dahong Yao*. (+)-Miliusol suppresses the Warburg effect and inducesregulated cell death in triple-negative breast cancer through targeting ElF3D andremodeling cancer metabolism. Acta Pharmaceutica Sinica B. 2025.

5. Jin Zhang^#, Xiaoling Cheng^#, Gang Chen^#, Xiya Chen, Xi Zhao, Weiji Chen, Wei Du, Zhendan He, Xiaojun Yao*, Bo Han*, Dahong Yao*. Discovery of a Novel Selective PAK1/HDAC6/HDAC10 Inhibitor ZMF-25 that Induces Mitochondrial Metabolic Breakdown and Autophagy-Related Cell Death in Triple Negative Breast Cancer. Research. 2025, 8:0670.

6. Zhiying Liu^#, Le Zhou^#, Shuangshuang Ma^#, Yaping Guo, Zhendan He, Jinhui Wang, Shuyun Wang*, Dahong Yao*, Yan Wu*. Tenuistones A–H, novel flavonoid derivatives from Miliusa tenuistipitata with anti-proliferative and anti-migration activities against triple-negative breast cancer cells. Bioorg Med Chem. 2025, 131:118430.

7. Minru Liao^#, Dahong Yao^#, Lifeng Wu^#, Chaodan Luo, Zhiwen Wanga, Jin Zhangc, Bo Liu*. Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer. Acta Pharmaceutica Sinica B. 2024,14(3):953-1008.

8. QianQian Yang^#, Chen Chen^#, Dahong Yao^#, Wei Liu, Bo Liu*, Jin Zhou, Dabo Pan, Cheng Peng, Gu Zhan*, Bo Han*. Catalytic Atroposelective Synthesis of Axially Chiral Azomethine Imines and Neuroprotective Activity Evaluation. Angew Chem Int Ed Engl. 2024, 63(5):e202312663.

9. Xi Zhao, Xiaoling Cheng, Zhiying Liu, Weiji Chen, Wenli Hao, Shuangshuang Ma, Jin Zhang*, Wei Huang*, Dahong Yao*. Design, synthesis and biological evaluation of plant-derived miliusol derivatives achieve TNBC profound regression in vivo. Eur J Med Chem. 2024, 279: 116882.

10. 1Jiacun Li^#, Ke Zhang^#*, Mei Xu^#, Huanyue Cui, Yaping Guo, Dahong Yao*,Wenhua Chen, Huaimin Liang, Hangyu Wang, Jinhui Wang*. Baicalin-2-ethoxyethyl ester alleviates renal fibrosis by inhibiting PI3K/AKT/NF-κB signaling pathway. Toxicol Appl Pharmacol. 2024, 483:116827.

11. Xuetao Yang^#, Ge Ge^#, Hailin Wang^#, Tianli Liu, Dabo Pan, Xi Zhao, Xiya Chen, Jinhui Wang, Jin Zhang*, Ke Zhang*, Dahong Yao*. Design, synthesis and biological evaluation of novel SIRT3 inhibitors targeting both NAD+ and substrate binding sites for the treatment of acute myeloid leukemia. Eur J Med Chem. 2024, 276: 116689.

12. Yi Du^#, Xiya Chen^#, Weiji Chen^#, Gang Chen, Xiaoling Cheng, Hailing Wang, Ling Guo, Chenyang Li*, Dahong Yao*. Design, synthesis and biological evaluation of a novel PAK1 degrader for the treatment of triple negative breast cancer. Bioorg Med Chem. 2024, 112:117896.

13.  Guichan Huang^#, Hailing Wang^#, Xi Zhao, Chen Wang, Jin Zhang, Dahong Yao*, Chenyang Li*. Design, synthesis and biological evaluation of new SIRT3 activators for the treatment of triple-negative breast cancer. Bioorg Med Chem. 2024, 118:118040.

14. Wenke Jin^#, Jin Zhang^#, Xiya Chen, Siwen Yin, Haiyang Yu*, Feng Gao*, Dahong Yao*. Unraveling the complexity of histone-arginine methyltransferase CARM1 in cancer: From underlying mechanisms to targeted therapeutics. Biochim Biophys Acta Rev Cancer. 2023, 1878: 188916.

15. Jiahui Fu^#, Jin Zhang^#, Xiya Chen^#, Zhiying Liu, Xuetao Yang, Zhendan He, Yue Hao*, Bo Liu*, Dahong Yao*.ATPase family AAA domain-containing protein 2(ATAD2): From an epigenetic modulator to cancer therapeutic target. Theranostics. 2023, 13(2): 787-809.

16. Jiahui Zhang^#, Jin Zhang^#, Hua Li*, Lixia Chen*, Dahong Yao*. Dual-target inhibitors of PARP1 in cancer therapy: a drug discovery perspective. Drug Discovery Today. 2023, 28:1-12.

17. Jin Zhang, Xiya Chen, Gang Chen, Hailing Wang, Lin Jia*, Yue Hao*, Dahong Yao*. Identification of a Novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulinstathmin regulated cell death in triple negative breast cancer. International Journal of Biological Macromolecules. 2023, 14:126348.

18. Dahong Yao^#, Jieshu You^#, Xuetao Yang, Jin Zhang*, Xiaojun Yao*. Fragment-based design, synthesis and biological evaluation of theophylline derivatives as ATAD2 inhibitors in BT-549 cells. J Enzyme Inhib Med Chem. 2023, 38(1):2242601.

19. Xuehai Jia, Ke Zhang*, Shushu Feng, Yuyao Li, Dahong Yao*, Qiaohui Liu, Dong Liu, Xin Li, Jian Huang, Hangyu Wang*, Jinhui Wang. Total glycosides of Rhodiola rosea L. attenuate LPS-induced acute lung injury by inhibiting TLR4/NF-κB pathway. Biomedicine & Pharmacotherapy, 2023, 158:114186.

20. Xiujun Xu^#, Meiling Zhang^#, Yanmin Hou^#, Ke zhang*, Dahong Yao*, Guoyu Li, Weibing Kou, Hangyu Wang, Jinhui Wang*. The Amomum tsao-ko Essential Oils Inhibited Inflammation and Apoptosis through p38/JNK MAPK Signaling Pathway and Alleviated Gentamicin-Induced Acute Kidney Injury. Molecules, 2022, 27(20):7121.

21. Zhengyin Pan, Wenwen Feng, Qiyan Liu, Liang He*, Dahong Yao*, ZhenDan He*. Lipophilic neutral iridium (III) complexes for phosphorescence imaging of lipid droplets and potential photodynamic therapy. Dyes and Pigments, 2022, 203:110387.

22. Dahong Yao, Jin Jiang, Hualin Zhang, Yelan Huang, Jian Huang*, Jinhui Wang*. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells. Bioorg Med Chem Lett. 2021, 47:128204.

23. Manman Tian^#, Zhenhao Tian^#, Dahong Yao^#, Jing Ning, Sa Deng, Lei Feng*, Xiaokui Huo, Xiangge Tian, Baojing Zhang, Chao Wang, Zhenlong Yu, Xiaochi Ma*. A NIR fluorescent probe for fatty acid amide hydrolase bioimaging and its application in development of inhibitors. J Mater Chem B. 2021, 9:6460-6465.

24. Xiangge Tian, Meirong Zhou, Jing Ning, Xiaopeng Deng, Lei Feng, Huilian Huang, Dahong Yao* Xiaochi Ma*. The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2. J ENZYM INHIB MED CH. 2021, 36(1):737-748.

25. Dahong Yao^#, Chenyang Li^#, Muhammad Shahid Riaz Rajoka, Zhendan He, Jian Huang, Jinhui Wang*, Jin Zhang*. P21-Activated Kinase 1: Emerging biological functions and potential therapeutic targets in cancer. Theranostics. 2020, 10(21):9741-9766.

26. Dahong Yao^#, Ruhan A^#, Jin Jiang, Jian Huang, Jinhui Wang*, Weina Han*. Design, synthesis and biological evaluation of 2-indolinone derivatives as PAK1 inhibitors in MDA-MB-231 cells. Bioorg Med Chem Lett. 2020, 30:127355.

27. Dahong Yao^#, Chenyang Li^#, Jin Jiang, Jian huang, Jinhui Wang, Zhendan He*, Jin Zhang*. Design, Synthesis and Biological evaluation of novel HDAC Inhibitors with improved pharmacokinetic profile in breast cancer, Eur J Med Chem. 2020, 112648.

28. Dahong Yao, Jin Zhang, Jinhui Wang, Dabo Pan^*, Zhendan He^*. Discovery of novel ATAD2 bromodomain inhibitors that trigger apoptosis and autophagy in breast cells by structure-based virtual screening. J ENZYM INHIB MED CH. 2020, 35(1): 713-725.

29. Dahong Yao, Jian huang, Jinhui Wang, Zhendan He*, Jin Zhang*. Design, synthesis and biological evaluation of novel tetrahydrothieno [2,3-c]pyridine substitued benzoyl thiourea derivatives as PAK1 inhibitors in triple negative breast cancer. J ENZYM INHIB MED CH. 2020, 35(1): 1524-1538.

30. Dahong Yao, Dabo Pan, Yongqi Zhen, Jian Huang, Jinhui Wang^*, Jin Zhang^*, Zhendan He^*. Ferulin C triggers potent PAK1 and p21-mediated anti-tumor effects in breast cancer by inhibiting Tubulin polymerization in vitro and in vivo. Pharmacol Res. 2020, 152:104605.

31. Jin Zhang*, Ling Zou, Pan Tang, Dabo Pan, Zhendan He, Dahong Yao^*. Design, Synthesis and biological evaluation of 1H-pyrazolo [3,4-d]pyrimidine derivatives as PAK1 inhibitors that trigger apoptosis, ER stress and anti-migration effect in MDA-MB-231 cells. Eur J Med Chem. 2020, 112220.

       联系方式：yaodahong@sztu.edu.cn